Gland Pharma has appointed Deepak Sapra as its new Chief Executive Officer, effective November 16, 2026. The company’s Board approved the appointment following a recommendation from the Nomination and Remuneration Committee, subject to Sapra’s acceptance of the offer.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Executive Profile

Deepak Sapra is a seasoned business leader with 27 years of executive experience, including over 23 years in the pharmaceutical industry. He currently serves as the Chief Executive Officer – API and Services at Dr. Reddy’s Laboratories Limited (DRL) and as a Board Member of Aurigene Pharma Services.

In his current role at DRL, Sapra is responsible for global portfolio strategy and leads an integrated B2B business spanning generic pharmaceuticals, CDMO services, APIs, collaborations and alliances, public health, and global patient access. His operations cover key markets including the United States, European Union, Japan, Brazil, China, Mexico, the Middle East, and emerging markets such as Africa.

Professional Background

Sapra’s prior experience includes serving as Chief Executive Officer – Custom Pharmaceutical Services, where he led a global CDMO business serving innovator pharmaceutical companies across the United States, Europe, and Japan. Between 2011 and 2015, he held senior leadership positions as Vice President – Global Generics Business Development and Senior Director – Global Generics Portfolio Management.

His expertise encompasses the end-to-end pharmaceutical value chain, including CDMO partnerships, generics, APIs, sales and marketing, international business management, business development, supply chain management, R&D, operations, portfolio strategy, public health, and access-led partnerships.

Education

Sapra holds a Bachelor's degree in Mechanical Engineering from the Indian Railways Institute of Mechanical and Electrical Engineering, Jamalpur, and a Master's degree in Management from the Indian Institute of Management, Bangalore. He was also a recipient of the Chevening Scholarship at the University of Bradford, UK, and a Fulbright Fellow at Carnegie Mellon University, Pittsburgh, USA.

Gland Pharma has entered into a strategic Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company to manufacture and supply a portfolio of sterile injectable products for global markets. The partnership establishes the Hyderabad-based firm as an integrated end-to-end partner, covering technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply under a full-service Contract Development and Manufacturing Organization (CDMO) model. This agreement provides significant long-term business visibility, with annualized revenue potential estimated at USD 90–100 million once all products are commercialized.

The filing was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additional details were provided under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The counterparty's name remains undisclosed due to confidentiality obligations, though it is identified as one of the leading global pharmaceutical companies.

Deal Structure and Product Portfolio

The agreement encompasses a diversified basket of oncology and non-oncology products in Vial, Lyo, Ampoules, and pre-filled syringe (PFS) presentations. These formulations cover both complex and conventional injectable types. Gland Pharma will leverage its integrated capabilities across development, technology transfer, manufacturing, quality, and regulatory support to provide a comprehensive "one-stop" solution. The current scope includes 55 Stock Keeping Units (SKUs) to be manufactured across three sites, with provisions to add more products in the near future.

Timeline and Execution

Technology transfer activities are planned for completion within two years. Revenues from this partnership are anticipated to commence from calendar year 2029. The collaboration supports multiple products across various stages of the product lifecycle, including both commercially marketed products and pipeline products under development. Srinivas Sadu, Executive Chairman of Gland Pharma, stated that the partnership highlights the confidence global pharmaceutical companies place in the company's development, technology transfer, manufacturing, and supply capabilities. He noted that the agreement supports the expansion of the CDMO business and creates a strong foundation for future growth.

What the Numbers Show

The commitment to 55 SKUs across three manufacturing sites indicates a substantial allocation of capacity and resources by Gland Pharma. While the revenue generation is deferred until calendar year 2029, the annualized potential of USD 90–100 million represents a significant addition to the company's top-line visibility. The inclusion of both oncology and non-oncology products in complex presentations like pre-filled syringes suggests a focus on high-value, technically demanding formulations rather than conventional low-margin generics. This diversification within the sterile injectables segment aligns with the company's strategy to deepen its integration as a full-service CDMO partner.